Product
GMCN-508B
1 clinical trial
1 indication
Indication
Beta-ThalassemiaClinical trial
An Open Label Study Evaluating the Safety and Efficacy of Gene Therapy for Transfusion-dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a LentiRed Lentiviral Vector (GMCN-508B Drug Product, Also Called LentiRed)Status: Recruiting, Estimated PCD: 2028-04-01